Business Wire

CA-VISA

2.2.2021 13:02:12 CET | Business Wire | Press release

Share
Visa Introduces AI-Powered Innovations for Smarter Payments

Visa Inc. (NYSE: V) today announced VisaNet +AI, a suite of AI-powered services that address long-standing challenges and pain points for banks, merchants and consumers—including delays and confusion with managing account balances and the unpredictability of daily settlement for financial institutions. VisaNet +AI comprises several innovative concepts and new value-added services, including Visa Smarter Posting and Visa Smarter Settlement Forecast, as well as Visa Smarter Stand-In Processing (Smarter STIP), a capability announced in August of last year. These innovations harness Visa’s high-performance AI platform to help make payments more predictable, transparent, and speedy.

“Our clients, partners and cardholders look to us for actionable data-driven insights to better manage their businesses and financial lives, especially during these unprecedented times. Today we’re announcing a set of services that use AI to make it easier for consumers to manage their accounts, and for financial institutions to manage their business,” said Jack Forestell, executive vice president and chief product officer, Visa. “With our investment in AI infrastructure, we’re unlocking novel, real-time solutions to complex problems. This is just the beginning of what we can do with the predictive power of AI.”

Smarter Posting helps provide greater transparency for consumers

Today’s digital-native consumers expect real-time visibility into their finances as they increasingly conduct banking on mobile and online platforms. However, the payment experience for consumers can be inconsistent, with some purchases taking longer to finalize on their balance than others. This lag can create confusion or concern for cardholders, resulting in increased call center volume or potential overdrafts.

This delay occurs because the amount authorized in real-time at the checkout counter can differ from the amount eventually cleared from a consumer’s account. For example, the final amount can change when a restaurant-goer adds a tip at a restaurant, or when a cross-border payment happens involving multiple currencies. To prevent consumer confusion from seeing multiple charges for a single transaction, banks often delay posting the payment or updating the account balance until they have certainty about the final amount.

To help issuers create a better banking experience for cardholders, Visa developed Smarter Posting, a service that uses AI to deliver a customized score for each transaction as part of the authorization process. The Smarter Posting model analyzes transaction details and historical data to predict the likelihood that a transaction amount will remain consistent through clearing. In testing, the model has achieved 98% accuracy1 in predicting whether the transaction amount will likely remain stable, giving financial institutions added intelligence to provide a more consistent end-to-end payment experience, for example, by provisionally updating the account balance that a cardholder sees.

Visa Smarter Posting will be initially available in Europe in April 2021 and is slated to expand globally in the near future.

Smarter Settlement Forecast uses predictive modeling to anticipate cash flow needs

Every day during the settlement process, Visa enables the movement of billions of dollars across thousands of institutions in more than 200 countries and territories and 160 currencies. It’s the final step in the payment cycle, where transactions are aggregated, transfers are facilitated between acquirers and issuers, and merchant accounts are credited for the sales they’ve made.

This process requires financial institutions to strategically allocate resources—so that there is enough liquidity to meet the day’s settlement volume, without over-allocating resources that could be leveraged elsewhere in their business. Today’s volatile environment has underscored the challenge treasury teams face in predicting daily volumes and making strategic decisions.

Visa created Smarter Settlement Forecast to provide clients with customized 7-day forecasts of the settlement amount they may need on hand each day. The service uses information generated by historical settlement volumes, seasonal indicators, macro-trends, outlier events, such as those surrounding COVID-19, and real-time transaction data to provide high quality predictions of cash outflows and inflows. These forecasts can help issuers and acquirers optimize treasury and liquidity management processes, and assist financial institutions settling in multiple currencies with predictions for each currency.

Smarter Settlement Forecast is slated to be made available to eligible clients through a subscription in the Visa Analytics Platform, thereby simplifying integration for clients. Visa is currently piloting the service with three clients ahead of its formal launch planned for later this year.

Smarter STIP can improve payment experiences during outages

Visa Smarter Stand-In Processing (Smarter STIP), the first of the VisaNet +AI capabilities announced in August 2020, has gained traction among leading financial institutions globally. Smarter STIP uses deep learning to help financial institutions increase transaction authorizations during outages. Smarter STIP generates an informed decision to approve or decline transactions on behalf of issuers to provide consumers with a frictionless Visa payment experience.

Since its release, Smarter STIP has seen strong issuer interest across every Visa region. In just two months, clients around the world have added Smarter STIP to their suite of Visa solutions, including Caixa Econômica Federal, and Doha Bank.

“In Visa we have a partner that is driving new innovations in AI for payments,” said Mr. Braik Ali H S Al – Marri, Chief Retail Banking Officer, Doha Bank, Qatar. “With VisaNet +AI we can harness those innovations and drive new value for our business and customers.”

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world, and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of digital commerce on any device for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa , visa.com/blog and @VisaNews .


1 Visa data based on analysis comparing the model prediction of when authorization and clearing amounts will remain consistent. Analysis conducted on historical transaction data (August - September 2020) for 150 million transactions.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release

Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates

Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release

Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye